Mark Schlosberg, MD
Pulmonary Disease · Marietta, GANPI 1851326318
Payments from drug & device makers
Across 376 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Boehringer Ingelheim$1K
- Jazz Pharmaceuticals Inc.$694
- Insmed, Inc.$527
- AstraZeneca$524
- Regeneron Healthcare Solutions, Inc.$440
- plus $3K from 30 others
What the payments were for
- Food & beverage$7,925100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 123 | $1,709 |
| Boehringer Ingelheim | 51 | $1,278 |
| Jazz Pharmaceuticals Inc. | 20 | $694 |
| Insmed, Inc. | 17 | $527 |
| AstraZeneca(2 entities) | 26 | $524 |
| Regeneron Healthcare Solutions, Inc. | 19 | $440 |
| Grifols USA, LLC | 18 | $383 |
| Sanofi | 13 | $380 |
| Verona Pharma, Inc. | 8 | $204 |
| Axsome Therapeutics, Inc. | 10 | $200 |
| United Therapeutics Corporation | 8 | $194 |
| Merck | 7 | $193 |
| Amgen | 9 | $175 |
| Pulmonx Corporation | 3 | $140 |
| Mallinckrodt Enterprises LLC | 4 | $116 |
| Mylan Specialty L.p. | 5 | $95 |
| Mallinckrodt Hospital Products Inc. | 3 | $86 |
| Baxter Healthcare | 4 | $75 |
| AbbVie(2 entities) | 3 | $64 |
| La Jolla Pharmaceutical Company | 3 | $51 |
| Genentech USA, Inc. | 2 | $47 |
| CSL Behring | 2 | $44 |
| Viatris Specialty LLC | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Actelion Pharmaceuticals US, Inc. | 2 | $36 |
| Nabriva Therapeutics, PLC | 2 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Vapotherm Inc | 1 | $21 |
| Bayer | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $19 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Electromed, Inc. | 1 | $14 |
| Pfizer | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Inogen, Inc. | 1 | $10 |
How this compares
$7,927 in reported general payments places this provider in the 60th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 49 | $570,962 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 290 | $222,727 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 191 | $98,231 |
| Breo ElliptaFluticasone/Vilanterol | 114 | $47,966 |
| Spiriva RespimatTiotropium Bromide | 48 | $38,045 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 54 | $31,239 |
| Arnuity ElliptaFluticasone Furoate | 82 | $24,408 |
| SymbicortBudesonide/Formoterol Fumarate | 64 | $17,838 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $13,985 |
| Spiriva HandihalerTiotropium Bromide | 20 | $12,295 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 382 | $10,435 |
| Advair HfaFluticasone Propion/Salmeterol | 31 | $9,249 |
| Fluticasone Propionate HfaFluticasone Propionate | 19 | $6,101 |
| Atrovent HfaIpratropium Bromide | 13 | $6,088 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 35 | $4,378 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,278 | $640,245151 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $1,709 | $393,333677 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $524 | $31,82380 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Marietta
- Hitendra PatelMarietta$104K
- Jeffrey MichaelsonMarietta$69K
- Amyn HiraniMarietta$68K
- Maria MascoloRincon$2.7M
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.